103 Results for "

STAT6

" in MedChemExpress (MCE) Product Catalog:
Products (103)

103 Results for "STAT6" in MCE Product Catalog:

  • Isoforms Recommended:
  • Targets Recommended:
Cat. No.: HY-134772
CAS No.: 909561-15-5
Purity:  98.10%
Target:  

STAT Cytochrome P450

Research Areas:  

Inflammation/Immunology

AS1810722 is an orally active and potent STAT6 inhibitor with an IC50 of 1.9 nM. AS1810722 shows a good profile of CYP3A4 inhibition. AS1810722, a derivative of fused bicyclic pyrimidine, has the potential for allergic diseases such as asthma and atopic diseases research .
loading...
    loading...
Cat. No.: HY-176919
CAS No.: 3077385-98-6
Target:  

PROTACs STAT

Research Areas:  

Inflammation/Immunology Cancer

PROTAC STAT6 degrader-3 is a potent STAT6 PROTAC degrader with a DC50 of less than 1 nM. PROTAC STAT6 degrader-3 can be used for research on allergic/inflammatory diseases and cancer .
loading...
    loading...
Cat. No.: HY-162405
CAS No.: 2949393-27-3
STAT6-IN-12 is a potent STAT6 inhibitor with an IC50 of 50 nM. STAT6-IN-12 also inhibits Smad2/3 with an IC50 of 68 nM. STAT6-IN-12 inhibits TGFβ-dependent Smad2/3 signaling pathway, IL-4-dependent STAT6 signaling pathway, and cellular inflammatory responses. STAT6-IN-12 can be used for the research of inflammation .
loading...
    loading...
Cat. No.: HY-153991
CAS No.: 1355594-85-2
Purity:  98.01%
Target:  

STAT

Research Areas:  

Inflammation/Immunology

STAT6-IN-2 (Compound R-84) is a STAT6 inhibitor that can inhibit the tyrosine phosphorylation of STAT6. STAT6-IN-2 can also inhibit the secretion of eotaxin-3. STAT6-IN-2 can be used in the research of immune diseases and allergic inflammatory diseases such as asthma .
loading...
    loading...
Cat. No.: HY-169360
CAS No.: 2497585-50-7
Target:  

PROTACs STAT

Research Areas:  

Cancer

SD-436 is a highly selective and efficacious STAT3 PROTAC degrader (DC50: 0.5 μM), with IC50 of 19 nM (STAT3), 270 nM (STAT1), 360 nM (STAT4), >10 μM (STAT5) and >10 μM (STAT6). SD-436 promotes ubiquitination and degradation of STAT3, and induces tumor regression. SD-436 can be used for tumor research, such as leukemia and lymphoma .
loading...
    loading...
Cat. No.: HY-148092
CAS No.: 1637532-77-4
Purity:  98.87%
Target:  

STAT

Research Areas:  

Inflammation/Immunology Cancer

PM-43I is a potent STAT6 inhibitor and can reduce STAT6 phosphorylation level. PM-43I can be used in allergic lung disease, allergic rhinitis, chronic pulmonary obstructive disease and cancer research [1].
loading...
    loading...
Cat. No.: HY-W1113771
CAS No.: 3033743-58-4
Research Areas:  

Inflammation/Immunology

STAT6-IN-7 is a STAT6 inhibitor. STAT6-IN-7 exhibits an IC50 of 0.28 μM for inhibiting the binding of human STAT6/pIL-4Rα. STAT6-IN-7 can be used in the research of atopic dermatitis .
loading...
    loading...
Cat. No.: HY-116474
CAS No.: 14484-44-7
Purity:  99.93%
Viridicatol is a quinolone alkaloid with anti-inflammatory, antibacterial, antifungal, osteogenic and chondrogenic activities. Viridicatol reduces the phosphorylation levels of ERK, JNK, p38 and STAT6; inhibits MMP-2, MMP-9, NF-κB signaling pathway and PTP1B; downregulates genes related to mast cell activation; and binds to SHN3 to activate the Wnt/SHN3 signaling pathway. Viridicatol inhibits the expression of pro-inflammatory mediators and cytokines, and promotes osteogenic/chondrogenic differentiation. Viridicatol can be used in studies related to fibrosarcoma, allergy, bacterial infection, fungal infection and osteoporosis .
loading...
    loading...
Cat. No.: HY-175650
CAS No.: 3092076-15-5
Research Areas:  

Inflammation/Immunology

STAT6-IN-9 is a potent STAT6 inhibitor with an EC50 value of 4 nM. STAT6-IN-9 effectively blocks STAT6 activation mediated by the IL-13-IL-13 receptor/IL-4 receptor pathway. STAT6-IN-9 inhibits CCL17 secretion with an IC50 value of 4.6 nM. STAT6-IN-9 can be used to investigate various chronic inflammatory diseases mediated by STAT6, such as allergy, asthma, and chronic obstructive pulmonary disease .
loading...
    loading...
Cat. No.: HY-N0566
CAS No.: 85999-40-2
Synonyms: Anemosapogenin
23-Hydroxybetulinic acid (Anemosapogenin) is an orally active triterpenoid with broad-spectrum anticancer activity. 23-Hydroxybetulinic acid reduces the levels of Bcl-2 and survivin, elevates the level of Bax, promotes the cleavage/activation of caspase-3 and caspase-9, and induces apoptosis via the endogenous mitochondrial pathway involving cytochrome C release and mitochondrial membrane potential disruption. 23-Hydroxybetulinic acid arrests the cell cycle at S and G1 phases, inhibits cancer cell proliferation, blocks the MAPK signaling pathway, regulates MMP2, and induces autophagic apoptosis by upregulating beclin-1. 23-Hydroxybetulinic acid inhibits the activity and efflux function of P-gp, increases the intracellular accumulation of chemotherapeutic drugs, and synergistically enhances cytotoxicity with Doxorubicin (HY-15142). 23-Hydroxybetulinic acid inhibits the phosphorylation and nuclear translocation of STAT6, blocks M2 macrophage polarization, and reduces M2 macrophage-mediated apoptosis resistance of colon cancer cells. 23-Hydroxybetulinic acid can be used in related studies on chronic myeloid leukemia, hepatocellular carcinoma, sarcoma 180, multidrug-resistant breast cancer, leukemia, Doxorubicin-induced cardiotoxicity, and colorectal cancer [6] .
loading...
    loading...
Cat. No.: HY-148093
CAS No.: 1637532-83-2
Purity:  99.91%
Target:  

STAT

Research Areas:  

Inflammation/Immunology Cancer

PM-81I is a potent STAT6 inhibitor (targeting the SH2 structural domain) that effectively reduces STAT6 phosphorylation levels. PM-81I can be used in studies of allergic lung disease, allergic rhinitis, chronic obstructive pulmonary disease or cancer [1].
loading...
    loading...
Cat. No.: HY-179233
CAS No.: 3105288-31-8
Target:  

PROTACs STAT

Research Areas:  

Others

PROTAC STAT6 degrader-2 is a STAT6-selective PROTAC degrader. PROTAC STAT6 degrader-2 is used for the research of STAT6-mediated diseases .
loading...
    loading...
Cat. No.: HY-176864
STAT6 ligand-1 is a ligand for STAT6. STAT6 ligand-1 can be used for synthesizing PROTACs such as STAT6 degrader-2 (HY-176857) .
loading...
    loading...
Cat. No.: HY-P990090
CAS No.: 2648260-80-2
Synonyms: CBP-201

Research Areas:  

Inflammation/Immunology

Rademikibart (CBP-201) is a human monoclonal antibody targeting IL-4Rα and IL-4Rα inhibitor with a KD of 20.7 pM when binding to human IL-4Rα epitopes . Rademikibart does not bind to IL-4Rα from other species. Rademikibart inhibits IL-4 and IL-13-mediated STAT6 signaling, TF-1 cell proliferation and thymus activation regulated chemokine (TRAC) production. Rademikibart can be used for the research of atopic dermatitis and asthma .
loading...
    loading...
Cat. No.: HY-RS13896
Research Areas:  

Others

STAT6 Human Pre-designed siRNA Set A contains three designed siRNAs for STAT6 gene (Human), as well as a negative control, a positive control, and a FAM-labeled negative control.

loading...
    loading...
Cat. No.: HY-162404
CAS No.: 1899061-36-9
(14S,15R)-14-Deoxyoxacyclododecindione (Compound 3) acts as an inhibitor of TGF-β-dependent Smad2/3 and IL-4-dependent STAT6, with IC50 values of 90 nM and 20 nM, respectively. (14S,15R)-14-deoxyoxacyclododecindione is a potent IL-4 inhibitor with an IC50
value of 20 nM. (14S,15R)-14-Deoxyoxacyclododecindione is applicable to the research of chronic inflammation and fibrotic diseases .
loading...
    loading...
Cat. No.: HY-161765
Target:  

HSP STAT

Research Areas:  

Cancer

iHSP110-33 is an inhibitor for heat shock protein 110 (HSP110). iHSP110-33 exhibits antitumor efficacy agaisnt large B-cell lymphoma and classical Hodgkin lymphoma. iHSP110-33 shows a synergistic effect with Selinexor (HY-17536), inhibits the STAT6 phosphorylation, and enhances its antitumor activity. .
loading...
    loading...
Cat. No.: HY-40354R
CAS No.: 477600-75-2
Synonyms: Tasocitinib (Standard); CP-690550 (Standard)
Tofacitinib (Standard) (Tasocitinib (Standard); CP-690550 (Standard)) is the analytical standard of Tofacitinib (HY-40354). This product is intended for research and analytical applications. Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [6] .
loading...
    loading...
Cat. No.: HY-40354S
CAS No.: 2256762-71-5
Synonyms: Tasocitinib-13C3; CP-690550-13C3
Tofacitinib- 13C3 (Tasocitinib- 13C3; CP-690550- 13C3) is the 13C-labeled Tofacitinib (HY-40354). Tofacitinib (Tasocitinib) is an orally active, blood-brain barrier permeable selective inhibitor of JAK1/JAK3. Tofacitinib blocks the JAK-STAT/NF-κB signaling pathway, inhibits cytokine signal transduction, phosphorylation of STAT1/STAT5, and suppresses innate and adaptive immune responses. Tofacitinib can be used in research related to major depressive disorder, rheumatoid arthritis, pulmonary diseases, systemic lupus erythematosus, and immune-mediated liver injury [6] .
loading...
    loading...
Cat. No.: HY-W1113770
CAS No.: 3033741-50-0
Target:  

STAT

Research Areas:  

Inflammation/Immunology

STAT6-IN-8 is a STAT6 inhibitor with an IC50 of 0.45 μmol/L. STAT6-IN-8 exhibits potential anti-inflammatory and anti-allergic effects. STAT6-IN-8 can be used for the research of atopic dermatitis .
loading...
    loading...